Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription Articles published in Am J Gastroenterol Retrieve available abstracts of 177 articles: HTML format

Single Articles

March 2026
1. SILVEY S, Patel N, Tsai SY, Nadeem M, et al
   Correction to Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.
   Am J Gastroenterol. 2026 Mar 9. doi: 10.14309/ajg.0000000000003941.
   PubMed    
   
   
   
2. MIYOSHI Y, Nishio A, Tatsumi N, Yoshida Y, et al
   Ciliated Hepatic Foregut Cyst with Clustered Echogenic Foci: An Incidental Finding on Health Screening.
   Am J Gastroenterol. 2026 Mar 6. doi: 10.14309/ajg.0000000000003993.
   PubMed    
   
   
   
3. YOHEI H, Sakaue T, Yoshimura S, Takedatsu H, et al
   A Continuous Metallic Stream: Endoscopic Salvage of Migrated Hepatic Artery Coils.
   Am J Gastroenterol. 2026 Mar 5. doi: 10.14309/ajg.0000000000003989.
   PubMed    
   
   
   
4. BAJAJ JS, Jakab SS, Jesudian AB, Rahimi RS, et al
   ACG Clinical Guideline: Hepatic Encephalopathy.
   Am J Gastroenterol. 2026;121:588-618.
   PubMed     Abstract available
   
   
   
5. BARRITT AS 4TH, Tapper EB, Newsome PN, Gazis D, et al
   Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
   Am J Gastroenterol. 2026;121:710-719.
   PubMed     Abstract available
   
   
   
6. JOHN BV, Bastaich D, Marchetti D, Perumalswami P, et al
   Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study.
   Am J Gastroenterol. 2026;121:697-709.
   PubMed     Abstract available
   
   
   February 2026
7. OCHOA-ALLEMANT P, Kiran A, Mezzacappa C, Kaplan DE, et al
   Steatotic Liver Disease Has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the U.S. Veterans Health System.
   Am J Gastroenterol. 2026 Feb 18. doi: 10.14309/ajg.0000000000003966.
   PubMed     Abstract available
   
   
   
8. TAPPER EB, Woodrell CD, Rakoski M, Huang R, et al
   Hepatic Encephalopathy is the Key Driver of Symptom Burden in a Longitudinal Cohort of Patients with Advanced Chronic Liver Disease: PAL-LIVER sub-study.
   Am J Gastroenterol. 2026 Feb 13. doi: 10.14309/ajg.0000000000003964.
   PubMed     Abstract available
   
   
   
9. PATEL N, Silvey S, Bajaj JS
   Vonoprazan Is Associated with Better Liver-Related Outcomes Compared to Proton Pump Inhibitors In Cirrhosis.
   Am J Gastroenterol. 2026 Feb 10. doi: 10.14309/ajg.0000000000003945.
   PubMed     Abstract available
   
   
   
10. CAVIGLIA GP, Ferro A, D'Ambrosio R, Perbellini R, et al
    Effectiveness of a Model of Care Based on Fibrosis-4 and Liver Stiffness Measurement for the Screening of Patients With Type 2 Diabetes Mellitus at Risk of Advanced Liver Disease: Results From an Italian Prospective Multicenter Study.
    Am J Gastroenterol. 2026;121:375-382.
    PubMed     Abstract available
    
    
    
11. ALKHOURI N, Cheuk-Fung Yip T, Castera L, Takawy M, et al
    ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Am J Gastroenterol. 2026;121:362-374.
    PubMed     Abstract available
    
    
    January 2026
12. SHABBIR R, Garrido-Trevino L, O'Leary JG, Chaudhary A, et al
    MELD-Lactate and lactate clearance in critically ill cirrhosis patients with sepsis.
    Am J Gastroenterol. 2026 Jan 27. doi: 10.14309/ajg.0000000000003934.
    PubMed     Abstract available
    
    
    
13. JARRAH M, Rich NE, Figueroa G, Garces SM, et al
    Treatment Delays and Survival in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Am J Gastroenterol. 2026 Jan 21. doi: 10.14309/ajg.0000000000003923.
    PubMed     Abstract available
    
    
    
14. XUE J, Zhang L, Xie N, Lei L, et al
    Primary hepatic somatostatinoma (G2) with diabetes and nodal metastasis: An exceptionally rare primary liver tumor.
    Am J Gastroenterol. 2026 Jan 9. doi: 10.14309/ajg.0000000000003908.
    PubMed    
    
    
    
15. SHROFF H, Shankar A, Baron A, Yoxheimer L, et al
    A Large Language Model Assistant for Summarizing Hepatology Referral Documents.
    Am J Gastroenterol. 2026 Jan 8. doi: 10.14309/ajg.0000000000003905.
    PubMed     Abstract available
    
    
    
16. AHMAD J, Dellinger A, Nicoletti P, Barnhart HX, et al
    Clinical and HLA Associations of Fluoroquinolone-Induced Liver Injury: Results From the Drug-Induced Liver Injury Network.
    Am J Gastroenterol. 2026;121:151-158.
    PubMed     Abstract available
    
    
    
17. LE P, Tatar M, Rothberg MB, Wilson LA, et al
    Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease.
    Am J Gastroenterol. 2026;121:159-170.
    PubMed     Abstract available
    
    
    December 2025
18. SHROFF H, Fix OK
    Practical Applications of Artificial Intelligence to Improve Efficiency and Reduce Burnout in Gastroenterology and Hepatology Practices.
    Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003887.
    PubMed    
    
    
    
19. CHOI J, Nguyen VH, Przybyszewski E, Song J, et al
    Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 Diabetes.
    Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003889.
    PubMed     Abstract available
    
    
    
20. ABU-RUMAILEH M, Dhoop S, Pace J, Qapaja T, et al
    Social Determinants of Health Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2025;120:2810-2820.
    PubMed     Abstract available
    
    
    November 2025
21. RODRIGUEZ N, Katzenstein C, Alpert L, Sigel K, et al
    Evaluating the 2023 EASL guidelines for intrahepatic cholestasis of pregnancy: risk stratification and outcomes in over 4,000 U.S. patients.
    Am J Gastroenterol. 2025 Nov 24. doi: 10.14309/ajg.0000000000003866.
    PubMed     Abstract available
    
    
    
22. PATIDAR KR, Hall L, Ogola GO, Pike F, et al
    Associations Between Mean Arterial Pressure Thresholds and Clinical Outcomes in Decompensated Cirrhosis With Septic Shock.
    Am J Gastroenterol. 2025 Nov 19. doi: 10.14309/ajg.0000000000003854.
    PubMed     Abstract available
    
    
    
23. SWAIN LA, Godley J, Wang M, Brahmania M, et al
    Temporal and demographic trends in alcohol-related-cirrhosis, alcohol-related hepatitis, and non-alcohol-related cirrhosis hospitalizations from 2012-2023: A population-based study in Alberta, Canada.
    Am J Gastroenterol. 2025 Nov 14. doi: 10.14309/ajg.0000000000003835.
    PubMed     Abstract available
    
    
    
24. SMITH L, Sciacca K, Durieux BN, Bizup G, et al
    Harnessing Natural Language Processing to Identify Documentation of Serious Illness Communication for Patients with Decompensated Cirrhosis.
    Am J Gastroenterol. 2025 Nov 14. doi: 10.14309/ajg.0000000000003830.
    PubMed     Abstract available
    
    
    
25. SILVEY S, Patel N, Davis BC, Sterling RK, et al
    Use of Natural language processing to objectively identify hepatic encephalopathy in multiple cohorts.
    Am J Gastroenterol. 2025 Nov 6. doi: 10.14309/ajg.0000000000003824.
    PubMed     Abstract available
    
    
    
26. BURTON R, Leggio L, Louvet A, Sheron N, et al
    Prevention of Alcohol-Associated Liver Disease.
    Am J Gastroenterol. 2025;120:2487-2501.
    PubMed     Abstract available
    
    
    
27. JOHN BV, Bastaich D, Mezzacappa C, Ferreira RD, et al
    Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.
    Am J Gastroenterol. 2025;120:2583-2591.
    PubMed     Abstract available
    
    
    
28. SHENOY A, Jasty VS, Uttal S, Nasser S, et al
    Medications for Alcohol Use Disorder Are Increasingly Being Prescribed in American Patients With Advanced Liver Disease.
    Am J Gastroenterol. 2025;120:2576-2582.
    PubMed     Abstract available
    
    
    
29. NIEZEN S, Morgan TR, Scott D, Yakovchenko V, et al
    Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans.
    Am J Gastroenterol. 2025;120:2559-2566.
    PubMed     Abstract available
    
    
    October 2025
30. DE FARIA MORAES B, Pedral Diniz Leite GA, Pedral Diniz Leite GA, Motta Fonseca ML, et al
    Reevaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-analysis.
    Am J Gastroenterol. 2025 Oct 21. doi: 10.14309/ajg.0000000000003800.
    PubMed     Abstract available
    
    
    
31. CHIRAPONGSATHORN S, Chang A, Malikhao S, Wanichagool D, et al
    One versus five days of octreotide infusion for acute esophageal variceal bleeding: a randomized controlled trial.
    Am J Gastroenterol. 2025 Oct 15. doi: 10.14309/ajg.0000000000003791.
    PubMed     Abstract available
    
    
    
32. ZHANG X, Ning C, Yang X
    The Illusion of Response: Diffuse Hepatic Metastasis Masked by Shrinking Lesions in Neuroendocrine Carcinoma of the Cervix.
    Am J Gastroenterol. 2025 Oct 10. doi: 10.14309/ajg.0000000000003788.
    PubMed    
    
    
    
33. BOIKE JR, Gallegos-Orozco JF, Duarte-Rojo A
    Rallentando un Poco : Carvedilol and Its Role in Cirrhosis Progression.
    Am J Gastroenterol. 2025 Oct 3. doi: 10.14309/ajg.0000000000003765.
    PubMed    
    
    
    
34. KHAN Z
    Continuing Medical Education Questions: October 2025.
    Am J Gastroenterol. 2025;120:2236.
    PubMed     Abstract available
    
    
    
35. RATTAN P, Ahn JC, Chara BS, Mullan AF, et al
    Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease.
    Am J Gastroenterol. 2025;120:2452-2456.
    PubMed     Abstract available
    
    
    
36. LEE HH, Lee HA, Kim EJ, Kim HY, et al
    Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study.
    Am J Gastroenterol. 2025;120:2321-2329.
    PubMed     Abstract available
    
    
    
37. WU C, Targher G, Byrne CD, Mao Y, et al
    Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021.
    Am J Gastroenterol. 2025;120:2280-2290.
    PubMed     Abstract available
    
    
    
38. KIM WR, Mannalithara A, Charu V, Chung N, et al
    Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Am J Gastroenterol. 2025;120:2312-2320.
    PubMed     Abstract available
    
    
    
39. LUTZ MK, Caldera F
    Vaccination Outcomes and Recommendations Among Older Adults in a Gastroenterology and Hepatology Practice.
    Am J Gastroenterol. 2025;120.
    PubMed    
    
    
    
40. BROWN CL, Bajaj JS
    Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults.
    Am J Gastroenterol. 2025;120.
    PubMed    
    
    
    September 2025
41. PATEL AA, O'Leary JG, Bajaj JS, Prause N, et al
    Increasing Goals of Care Discussions Among Veterans with Cirrhosis: A Veterans Health Administration Quality Improvement Initiative.
    Am J Gastroenterol. 2025 Sep 29. doi: 10.14309/ajg.0000000000003781.
    PubMed     Abstract available
    
    
    
42. HASJIM BJ, Patel M, Chen S, Ichii H, et al
    Social Determinants of Health and Liver Transplant Outcomes in U.S. Indigenous Populations.
    Am J Gastroenterol. 2025 Sep 26. doi: 10.14309/ajg.0000000000003770.
    PubMed     Abstract available
    
    
    
43. MAHMUD N, Fricker ZP, McElroy LM, Qayed E, et al
    ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis.
    Am J Gastroenterol. 2025;120:1968-1984.
    PubMed     Abstract available
    
    
    
44. NIU C, Sun K, Zhang J, Elkhapery A, et al
    Gastrointestinal and Hepatobiliary Safety of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
    Am J Gastroenterol. 2025 Sep 3. doi: 10.14309/ajg.0000000000003760.
    PubMed     Abstract available
    
    
    August 2025
45. JEFFREY AW, Majumdar A, Jeffrey G, Calzadilla-Bertot L, et al
    The Portal Hypertension Decompensation Score - A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension.
    Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003744.
    PubMed     Abstract available
    
    
    
46. PRAKASH JH, Anirvan P, Gupta S, Chouhan MI, et al
    Diagnostic Accuracy of Spleen-dedicated 100 Hz Transient Elastography to Predict High-risk Esophageal Varices.
    Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003741.
    PubMed     Abstract available
    
    
    July 2025
47. RANA R, Tabish M, Agarwal S, Bayye R, et al
    Simvastatin addition to standard of care improves long-term survival in patients with cirrhosis after variceal bleed: An open label randomized controlled trial.
    Am J Gastroenterol. 2025 Jul 31. doi: 10.14309/ajg.0000000000003689.
    PubMed     Abstract available
    
    
    
48. OUYANG MM G, Chen Mm X, Yao Mm X, Mo Mm X, et al
    Unprecedented Duodenal Erosion of a Transjugular Intrahepatic Portosystemic Shunt Stent: A Rare Trigger for Recurrent Polymicrobial Sepsis.
    Am J Gastroenterol. 2025 Jul 30. doi: 10.14309/ajg.0000000000003680.
    PubMed    
    
    
    
49. NGUYEN NV, Sandstrom A, Dominicus A, Mageau A, et al
    Thiopurines and intrahepatic cholestasis of pregnancy in systemic lupus erythematosus and inflammatory bowel disease pregnancies.
    Am J Gastroenterol. 2025 Jul 23. doi: 10.14309/ajg.0000000000003652.
    PubMed     Abstract available
    
    
    
50. KHAJURIA R, Jindal A, Sharma MK, Arora V, et al
    Efficacy and safety of carvedilol in cirrhosis patients with new-onset uncomplicated ascites without high-risk esophageal varices. (CARVE-AS Trial).
    Am J Gastroenterol. 2025 Jul 21. doi: 10.14309/ajg.0000000000003650.
    PubMed     Abstract available
    
    
    
51. WOLTSCHE J, Pacher-Deutsch C, Furst S, Gulden L, et al
    Microbial Dysbiosis in the Urinary Microbiome of Patients with Cirrhosis.
    Am J Gastroenterol. 2025 Jul 7. doi: 10.14309/ajg.0000000000003634.
    PubMed     Abstract available
    
    
    
52. ZHANG K, Zhang L, Zhang J, Lu X, et al
    Unexpected Origin: Gastric Mature Cystic Teratoma Presenting as a Hepatic Mass.
    Am J Gastroenterol. 2025 Jul 2. doi: 10.14309/ajg.0000000000003621.
    PubMed    
    
    
    June 2025
53. CHAPMAN B, Sinclair M, Majumdar A, Yu C, et al
    Real-world experience of home continuous terlipressin infusion for complications of portal hypertension.
    Am J Gastroenterol. 2025 Jun 11. doi: 10.14309/ajg.0000000000003589.
    PubMed     Abstract available
    
    
    
54. PEREZ-DIAZ-DEL-CAMPO N, Castelnuovo G, Ferro A, Caviglia GP, et al
    Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohor
    Am J Gastroenterol. 2025;120:1779-1790.
    PubMed     Abstract available
    
    
    
55. SOGBE M, Wong R, Bloomer PM, Steinberg A, et al
    Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with advanced chronic liver disease.
    Am J Gastroenterol. 2025 Jun 9. doi: 10.14309/ajg.0000000000003583.
    PubMed     Abstract available
    
    
    May 2025
56. DESAI AP, Scherer AN, Serper M
    The Role of Patient-Reported Outcomes in Cirrhosis.
    Am J Gastroenterol. 2025 May 20. doi: 10.14309/ajg.0000000000003551.
    PubMed     Abstract available
    
    
    
57. HWANG SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, et al
    Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Am J Gastroenterol. 2025 May 16. doi: 10.14309/ajg.0000000000003546.
    PubMed     Abstract available
    
    
    
58. SOUZA M, Al-Sharif L, Diaz I, Khalil SM, et al
    Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates.
    Am J Gastroenterol. 2025 May 5. doi: 10.14309/ajg.0000000000003520.
    PubMed     Abstract available
    
    
    
59. SINGAL AK, Wong RJ, Dasarathy S, Abdelmalek MF, et al
    ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease.
    Am J Gastroenterol. 2025;120:950-972.
    PubMed     Abstract available
    
    
    
60. THOMAS A
    Continuing Medical Education Questions: May 2025.
    Am J Gastroenterol. 2025;120:948.
    PubMed     Abstract available
    
    
    April 2025
61. WALKER T, Alejandro-Soto A, Nephew L, Jones P, et al
    Association of Social Isolation From Living Alone and Psychological Distress Among Adults With Chronic Liver Disease in the United States.
    Am J Gastroenterol. 2025;120:1860-1864.
    PubMed     Abstract available
    
    
    
62. SINGAL AG, Yang JD, Jalal PK, Salgia R, et al
    Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.
    Am J Gastroenterol. 2025;120:1800-1808.
    PubMed     Abstract available
    
    
    
63. MOON AM, Lupu GV, Green EW, Deutsch-Link S, et al
    Rural-urban disparities in hepatocellular carcinoma deaths are driven by hepatitis C-related HCC.
    Am J Gastroenterol. 2025 Apr 11. doi: 10.14309/ajg.0000000000003487.
    PubMed     Abstract available
    
    
    
64. KUMAR A, Arora A, Choudhury A, Arora V, et al
    Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure.
    Am J Gastroenterol. 2025;120:816-826.
    PubMed     Abstract available
    
    
    March 2025
65. GARRIDO-TREVINO L, Ahn S, Tapper EB, Walker OC, et al
    Diagnosis of Acute on Chronic Liver Failure in critically ill patients with cirrhosis using administrative data.
    Am J Gastroenterol. 2025 Mar 17. doi: 10.14309/ajg.0000000000003422.
    PubMed     Abstract available
    
    
    February 2025
66. CHOLANKERIL G, Taylor T, Kramer JR, Liu Y, et al
    Inequalities in developing cirrhosis complications over time: A cohort study.
    Am J Gastroenterol. 2025 Feb 5. doi: 10.14309/ajg.0000000000003354.
    PubMed     Abstract available
    
    
    
67. YUN B, Park H, Ahn SH, Oh J, et al
    Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Am J Gastroenterol. 2025;120:410-419.
    PubMed     Abstract available
    
    
    January 2025
68. DECHARATANACHART P, Poovorawan K, Tangkijvanich P, Charatcharoenwitthaya P, et al
    Cost-Utility Analysis of Non-Invasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Am J Gastroenterol. 2025 Jan 29. doi: 10.14309/ajg.0000000000003332.
    PubMed     Abstract available
    
    
    
69. ROMAIN D, Hao S, Grzyb K, Bashaw L, et al
    Electronic Interventions to Improve Quality for Inpatient Cirrhosis Care: a prospective evaluation.
    Am J Gastroenterol. 2025 Jan 29. doi: 10.14309/ajg.0000000000003334.
    PubMed     Abstract available
    
    
    
70. GHANDOUR B, Kaplan DE, Mahmud N
    High Cirrhosis Surgical Volume Centers have Reduced Postoperative Mortality in Patients with Cirrhosis Undergoing Major Surgery.
    Am J Gastroenterol. 2025 Jan 21. doi: 10.14309/ajg.0000000000003329.
    PubMed     Abstract available
    
    
    
71. MORITA M, Takita M, Nishida N, Kudo M, et al
    Giant Sister Mary Joseph;s nodule in Hepatocellular Carcinoma.
    Am J Gastroenterol. 2025 Jan 17. doi: 10.14309/ajg.0000000000003325.
    PubMed    
    
    
    
72. SILVEY S, Patel N, O'Leary JG, Bajaj JS, et al
    ENHANCEMENT OF CIRRHOSIS MORTALITY PREDICTION BY INCLUDING HEPATIC ENCEPHALOPATHY TO MELD3.0 IN A NATIONAL VETERAN COHORT.
    Am J Gastroenterol. 2025 Jan 16. doi: 10.14309/ajg.0000000000003317.
    PubMed     Abstract available
    
    
    
73. BERAN A, Elfert K, Patel FN, Mohamed M, et al
    Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients With Cirrhosis: A Propensity-Matched Analysis of the US Collaborative Network.
    Am J Gastroenterol. 2025 Jan 16. doi: 10.14309/ajg.0000000000003322.
    PubMed     Abstract available
    
    
    
74. WONG F, Vagas HE, Reddy KR, Pagadala MR, et al
    The Effects of alfapump on Ascites Control and Quality of Life in Patients with Cirrhosis and Recurrent or Refractory Ascites.
    Am J Gastroenterol. 2025 Jan 6. doi: 10.14309/ajg.0000000000003300.
    PubMed     Abstract available
    
    
    December 2024
75. QIAO Y, Yang L, Yang H, Zheng M, et al
    Longitudinal Associations Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Subclinical Cardiovascular Measures in Chinese Children.
    Am J Gastroenterol. 2024;120:1395-1399.
    PubMed     Abstract available
    
    
    
76. SINGAL AK, Pannerselvam D, Arab JP, Im G, et al
    Delisting From Liver Transplant List for Improvement and Re-compensation Among Decompensated Patients at one-year.
    Am J Gastroenterol. 2024 Dec 23. doi: 10.14309/ajg.0000000000003259.
    PubMed     Abstract available
    
    
    
77. MALIK S, Frey LJ, Gutman J, Mushtaq A, et al
    Evaluating Artificial Intelligence-Driven Responses to Acute Liver Failure Queries: A Comparative Analysis Across Accuracy, Clarity, and Relevance.
    Am J Gastroenterol. 2024;120:2081-2085.
    PubMed     Abstract available
    
    
    
78. LEDENKO M, Patel T
    Poverty Traps and Mortality From Liver Diseases in the United States.
    Am J Gastroenterol. 2024;119:2462-2470.
    PubMed     Abstract available
    
    
    November 2024
79. WONG F, Reddy KR, Tandon P, Lai JC, et al
    Sex differences in patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites.: Sex Differences in Ascites Burden Perception.
    Am J Gastroenterol. 2024 Nov 27. doi: 10.14309/ajg.0000000000003251.
    PubMed     Abstract available
    
    
    
80. PACHISIA AV, Agarwal A, Mehta S, Kumari A, et al
    Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet.
    Am J Gastroenterol. 2024 Nov 26. doi: 10.14309/ajg.0000000000003244.
    PubMed     Abstract available
    
    
    
81. SHAH N, Sanyal AJ
    A PRAGMATIC MANAGEMENT APPROACH FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOSIS AND STEATOHEPATITIS.
    Am J Gastroenterol. 2024 Nov 21. doi: 10.14309/ajg.0000000000003215.
    PubMed    
    
    
    
82. NIE C, Vaska M, Wong JK, Bathe OF, et al
    Tumor Seeding With Needle Biopsy of Hepatocellular Carcinoma: A Systematic Review.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003210.
    PubMed     Abstract available
    
    
    
83. LAURENZANO J, Ganesan P, Harrington C, Slaughter JC, et al
    Post-Transjugular Intrahepatic Portosystemic Shunt Right Atrial Pressure and Left Atrial Volume Index Predict Heart Failure and Mortality: Dual Center Experience.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003211.
    PubMed     Abstract available
    
    
    
84. HUANG Y, Huang H, Wei T, Zhang A, et al
    Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States.
    Am J Gastroenterol. 2024;120:1367-1380.
    PubMed     Abstract available
    
    
    
85. SERPER M, Pulaski ME, Zhang S, Taddei TH, et al
    Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.
    Am J Gastroenterol. 2024;120:2059-2071.
    PubMed     Abstract available
    
    
    
86. BATHEJA MA
    Continuing Medical Education Questions: November 2024.
    Am J Gastroenterol. 2024;119:2172.
    PubMed     Abstract available
    
    
    
87. SINGAL AG, Parikh ND, Shetty K, Han SH, et al
    Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study.
    Am J Gastroenterol. 2024;119:2251-2258.
    PubMed     Abstract available
    
    
    October 2024
88. BHUSHAN S, Sohal A, Kowdley KV, Agaf FF, et al
    Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.
    Am J Gastroenterol. 2024 Oct 31. doi: 10.14309/ajg.0000000000003174.
    PubMed     Abstract available
    
    
    
89. MURNANE PM, Afshar M, Chamie G, Cook RL, et al
    Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.
    Am J Gastroenterol. 2024;120:1567-1575.
    PubMed     Abstract available
    
    
    
90. CHEN VL, Oliveri A, Raut C, Chen Y, et al
    TM6SF2-rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort: TM6SF2 effects on liver and cardiac outcomes.
    Am J Gastroenterol. 2024 Oct 30. doi: 10.14309/ajg.0000000000003169.
    PubMed     Abstract available
    
    
    
91. HASJIM BJ, Harris A, Balbale SN, Obayemi JE, et al
    Social Disadvantage and Disparities in Chronic Liver Disease: A Systematic Review.
    Am J Gastroenterol. 2024;120:1548-1566.
    PubMed     Abstract available
    
    
    
92. KIM NJ, Vutien P, Borgerding JA, Beste LA, et al
    Hepatic steatosis estimated by VCTE-derived CAP scores was associated with lower risks of liver-related events and all-cause mortality in patients with chronic liver disease.
    Am J Gastroenterol. 2024 Oct 25. doi: 10.14309/ajg.0000000000003161.
    PubMed     Abstract available
    
    
    
93. UFERE NN, Zeng C, Donlan J, Shalev D, et al
    Psychological Distress is Prevalent and Interdependent Among Patients with Decompensated Cirrhosis and Their Caregivers.
    Am J Gastroenterol. 2024 Oct 25. doi: 10.14309/ajg.0000000000003158.
    PubMed     Abstract available
    
    
    
94. MOON AM
    Raising the Bar: Is Hepatocellular Carcinoma Surveillance Warranted for Patients With Alcohol-Associated Cirrhosis?
    Am J Gastroenterol. 2024 Oct 24. doi: 10.14309/ajg.0000000000003123.
    PubMed    
    
    
    
95. BARRITT AS 4TH, Hayashi PH, Stolz AA, Barnhart H, et al
    Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database.
    Am J Gastroenterol. 2024;120:1307-1313.
    PubMed     Abstract available
    
    
    
96. CIRICILLO J, Myer A, Yeboah-Korang A, Osman A, et al
    Improving the Diagnostic Accuracy of RECAM in North American Patients With Suspected Idiosyncratic Drug-Induced Liver Injury.
    Am J Gastroenterol. 2024;120:1325-1333.
    PubMed     Abstract available
    
    
    
97. JM E, E V, Nm I
    Predicting and preventing bleeding in patients with cirrhosis undergoing procedures.
    Am J Gastroenterol. 2024 Oct 9. doi: 10.14309/ajg.0000000000003129.
    PubMed    
    
    
    
98. VERMA N, Roy A, Valsan A, Garg P, et al
    Liver Dysfunction and Systemic Inflammation Drive Organ Failures in Acute Decompensation of Cirrhosis: A Multi-Centric Study.
    Am J Gastroenterol. 2024 Oct 4. doi: 10.14309/ajg.0000000000003115.
    PubMed     Abstract available
    
    
    
99. LANZ-ZUBIRIA L, Chavez-Tapia NC
    To Continue or Discontinue beta-Blockers in Secondary Prophylaxis? That is the Dilemma.
    Am J Gastroenterol. 2024;119:2143.
    PubMed    
    
    
    
100. TANAKA T, Vander Weg M, Jones MP, Wehby G, et al
     Assessment of the 2021 AASLD Practice Guidance for Albumin Infusion in Elective Therapeutic Paracentesis: A Regression Discontinuity Design.
     Am J Gastroenterol. 2024;119:2045-2051.
     PubMed     Abstract available
     
     
     
101. ZAVER HB, Rajpal N, Shah NL, Argo CK, et al
     MELD and MELD 3.0: What It Means for Your Practice.
     Am J Gastroenterol. 2024;119:1951-1954.
     PubMed    
     
     
     September 2024
102. JUTRAS G, Flemming JA
     Global Epidemiology of Cirrhosis in Women.
     Am J Gastroenterol. 2024 Sep 19. doi: 10.14309/ajg.0000000000003086.
     PubMed     Abstract available
     
     
     
103. JENSEN MD, West PJ, Crooks C, Morling JR, et al
     Primary liver cancer risk and mortality in patients with alcohol-related cirrhosis in England and Denmark: observational cohort studies.
     Am J Gastroenterol. 2024 Sep 9. doi: 10.14309/ajg.0000000000003077.
     PubMed     Abstract available
     
     
     
104. SILVEY S, Patel NR, Tsai SY, Nadeem M, et al
     Higher Rate of SBP Recurrence with Secondary SBP Prophylaxis Compared to No Prophylaxis in Two National Cirrhosis Cohorts.
     Am J Gastroenterol. 2024 Sep 4. doi: 10.14309/ajg.0000000000003075.
     PubMed     Abstract available
     
     
     
105. WONG RJ, Yang Z, Yeoh A, Do A, et al
     Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
     Am J Gastroenterol. 2024;119:1841-1848.
     PubMed     Abstract available
     
     
     August 2024
106. KRONSTEN VT, Shawcross DL
     Clinical implications of inflammation in patients with cirrhosis.
     Am J Gastroenterol. 2024 Aug 27. doi: 10.14309/ajg.0000000000003056.
     PubMed     Abstract available
     
     
     
107. KOWDLEY KV, Hirschfield GM, Coombs C, Malecha ES, et al
     COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.
     Am J Gastroenterol. 2024 Aug 14. doi: 10.14309/ajg.0000000000003029.
     PubMed     Abstract available
     
     
     
108. LI M, Shu W, Zou Y, Xiao H, et al
     Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study.
     Am J Gastroenterol. 2024;119:1640-1643.
     PubMed     Abstract available
     
     
     
109. BARRITT AS 4TH, Yu F, Mospan AR, Newsome PN, et al
     High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
     Am J Gastroenterol. 2024;119:1624-1627.
     PubMed     Abstract available
     
     
     
110. VANDERSCHUEREN E, Armandi A, Kwanten W, Cassiman D, et al
     Spleen Stiffness-Based Algorithms Are Superior to Baveno VI Criteria to Rule Out Varices Needing Treatment in Patients With Advanced Chronic Liver Disease.
     Am J Gastroenterol. 2024;119:1515-1524.
     PubMed     Abstract available
     
     
     
111. STERLING RK, Vilar-Gomez E, Wilson LA, Loomba R, et al
     Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease.
     Am J Gastroenterol. 2024;119:1483-1495.
     PubMed     Abstract available
     
     
     
112. FONTANA RJ, Li YJ, Vuppalanchi R, Kleiner DE, et al
     ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study.
     Am J Gastroenterol. 2024;119:1496-1505.
     PubMed     Abstract available
     
     
     
113. LIU C, Cao Z, Yan H, Wong YJ, et al
     Correction to: A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
     Am J Gastroenterol. 2024;119:1706.
     PubMed    
     
     
     July 2024
114. WANG RX, Serper M, Taddei TH, Kaplan DE, et al
     The Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
     Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002976.
     PubMed     Abstract available
     
     
     
115. SHENOY A, Valicevic AN, Lin A, Su GL, et al
     Delivery of Outpatient Cirrhosis Care Via Tele-visit is Not Associated with Increased Mortality as Compared to Traditional In-Person Visits.
     Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002979.
     PubMed     Abstract available
     
     
     
116. TAPPER EB, Goldberg D, Parikh ND, Terrault NA, et al
     The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.
     Am J Gastroenterol. 2024 Jul 17. doi: 10.14309/ajg.0000000000002953.
     PubMed     Abstract available
     
     
     
117. KAZUMORI H, Saima A, Ohno Y
     Development of Giant Hepatocellular Carcinoma Leads to Biliary Plastic Stent Compression Resulting in Pseudoaneurysm Rupture in Right Hepatic Artery.
     Am J Gastroenterol. 2024 Jul 8. doi: 10.14309/ajg.0000000000002938.
     PubMed    
     
     
     
118. ARTZNER T, Goldberg DS, Sundaram V, Faitot F, et al
     Improvement in survival after transplantation for critically ill patients with cirrhosis in the United States.
     Am J Gastroenterol. 2024 Jul 5. doi: 10.14309/ajg.0000000000002944.
     PubMed     Abstract available
     
     
     
119. LOUISSAINT J, Kyalwazi B, Deng J, Melendez-Torres J, et al
     Patients With Cirrhosis Rapidly Review Potentially Abnormal Hepatocellular Carcinoma Surveillance Results Through the Patient Portal.
     Am J Gastroenterol. 2024 Jul 3. doi: 10.14309/ajg.0000000000002940.
     PubMed     Abstract available
     
     
     
120. FRENETTE C, Mendiratta-Lala M, Salgia R, Wong RJ, et al
     ACG Clinical Guideline: Focal Liver Lesions.
     Am J Gastroenterol. 2024;119:1235-1271.
     PubMed     Abstract available
     
     
     
121. ASKGAARD G, Jepsen P, Jensen MD, Kann AE, et al
     Population-Based Study of Alcohol-Related Liver Disease in England in 2001-2018: Influence of Socioeconomic Position.
     Am J Gastroenterol. 2024;119:1337-1345.
     PubMed     Abstract available
     
     
     June 2024
122. HUANG SC, Su TH, Tseng TC, Liao SH, et al
     Pre-existing and new-onset metabolic dysfunctions increase cirrhosis and its complication risks in chronic hepatitis B.
     Am J Gastroenterol. 2024 Jun 26. doi: 10.14309/ajg.0000000000002915.
     PubMed     Abstract available
     
     
     
123. BERAN A, Mohamed MFH, Vargas A, Aboursheid T, et al
     Early Diagnostic Paracentesis Improves Outcomes of Hospitalized Patients with Cirrhosis and Ascites: A Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2024 Jun 25. doi: 10.14309/ajg.0000000000002906.
     PubMed     Abstract available
     
     
     
124. ELHENCE H, Dodge JL, Kahn JA, Lee BP, et al
     Characteristics and Outcomes Among U.S. Commercially Insured Transgender Adults with Cirrhosis: A National Cohort Study.
     Am J Gastroenterol. 2024 Jun 25. doi: 10.14309/ajg.0000000000002907.
     PubMed     Abstract available
     
     
     
125. PARVATANENI S, Sarkis Y, Haugh M, Baker B, et al
     A comprehensive evaluation of emergency department utilization by patients with cirrhosis.
     Am J Gastroenterol. 2024 Jun 24. doi: 10.14309/ajg.0000000000002905.
     PubMed     Abstract available
     
     
     
126. THABUT D, Rudler M, Weiss N
     Diagnosis of Overt Hepatic Encephalopathy With a New Algorithm: Follow-up Data Are Required.
     Am J Gastroenterol. 2024 Jun 3. doi: 10.14309/ajg.0000000000002856.
     PubMed    
     
     
     
127. PAIK JM, Duong S, Zelber-Sagi S, Lazarus JV, et al
     Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States.
     Am J Gastroenterol. 2024;119:1089-1101.
     PubMed     Abstract available
     
     
     May 2024
128. DANPANICHKUL P, Ng CH, Muthiah M, Suparan K, et al
     From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women.
     Am J Gastroenterol. 2024;119:893-909.
     PubMed     Abstract available
     
     
     April 2024
129. BAJAJ JS, Pimentel M
     Is Hepatic Encephalopathy the First True Disorder of Gut-Brain interaction?
     Am J Gastroenterol. 2024 Apr 22. doi: 10.14309/ajg.0000000000002824.
     PubMed    
     
     
     
130. HUME SJ, Holmes JA, Thompson AJ
     Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?
     Am J Gastroenterol. 2024 Apr 15. doi: 10.14309/ajg.0000000000002766.
     PubMed    
     
     
     
131. ERMINELLI D, Mangini C, Zarantonello L, Angeli P, et al
     Overt hepatic encephalopathy - more than meets the eye.
     Am J Gastroenterol. 2024 Apr 8. doi: 10.14309/ajg.0000000000002795.
     PubMed     Abstract available
     
     
     
132. KHANNA S, Shah NL, Argo CK
     Use of Phosphatidylethanol Testing in Patients With Liver Disease.
     Am J Gastroenterol. 2024;119:596-599.
     PubMed    
     
     
     
133. PERUMALSWAMI PV, Winder GS, Fernandez AC, Mellinger JL, et al
     Practical Considerations to Optimize Care for Patients With Alcohol-Associated Liver Disease in General Gastroenterology Practice.
     Am J Gastroenterol. 2024;119:591-595.
     PubMed    
     
     
     March 2024
134. CHEN YT, Chen TI, Yang TH, Yin SC, et al
     Long-term Risks for Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
     Am J Gastroenterol. 2024 Mar 27. doi: 10.14309/ajg.0000000000002778.
     PubMed     Abstract available
     
     
     
135. CHEN QF, Chen S, Yi JZ, Wang JL, et al
     Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation.
     Am J Gastroenterol. 2024 Mar 25. doi: 10.14309/ajg.0000000000002774.
     PubMed     Abstract available
     
     
     
136. LO GH, Yeh JH, Tseng CH, Chen TH, et al
     A non-inferiority trial comparing 2 days vs. 5 days of terlipressin and ceftriaxone in terms of 5-day rebleeding for patients with acute gastro-esophageal variceal hemorrhage.
     Am J Gastroenterol. 2024 Mar 25. doi: 10.14309/ajg.0000000000002776.
     PubMed     Abstract available
     
     
     
137. TABISH M, Agarwal S, Gopi S, Rana R, et al
     Randomized controlled trial of Intravenous ferric-carboxymaltose vs oral iron to treat iron deficiency anemia after variceal bleed in patients with cirrhosis.
     Am J Gastroenterol. 2024 Mar 22. doi: 10.14309/ajg.0000000000002775.
     PubMed     Abstract available
     
     
     
138. SAMALA N, Xin Y, Wilson LA, Yates K, et al
     Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype.
     Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002756.
     PubMed     Abstract available
     
     
     
139. HIRODE G, Hansen BE, Chen CH, Su TH, et al
     Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
     Am J Gastroenterol. 2024 Mar 8. doi: 10.14309/ajg.0000000000002718.
     PubMed    
     
     
     
140. ZHANG X, Daniel CR, Soltero V, Vargas X, et al
     A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients.
     Am J Gastroenterol. 2024;119:505-511.
     PubMed     Abstract available
     
     
     February 2024
141. SASAKI S, Schmidt S, Uldry E, Halkic N, et al
     Hepaticocholecystic Duct: Not a Myth but a Pitfall in Cholecystectomy.
     Am J Gastroenterol. 2024 Feb 19. doi: 10.14309/ajg.0000000000002725.
     PubMed    
     
     
     
142. LOUISSAINT J, Vargas HE
     Picture Perfect: Artificial Intelligence in the Management of Hepatic Encephalopathy.
     Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002659.
     PubMed    
     
     
     
143. BUI H, Kumar NG, Singal AG, Boparai J, et al
     Implementation of a hepatocellular carcinoma surveillance program in a community-based integrated health system in patients with hepatitis C cirrhosis.
     Am J Gastroenterol. 2024 Feb 9. doi: 10.14309/ajg.0000000000002704.
     PubMed     Abstract available
     
     
     
144. RANGRAY R
     Continuing Medical Education Questions: February 2024.
     Am J Gastroenterol. 2024;119:248.
     PubMed     Abstract available
     
     
     
145. BATHEJA MA
     Continuing Medical Education Questions: February 2024.
     Am J Gastroenterol. 2024;119:247.
     PubMed     Abstract available
     
     
     
146. MURPHY CC, Tavakkoli A, Wani S, Singal AG, et al
     Pandemic-Related Changes in Incidence and Mortality Rates of Gastrointestinal Cancers During 2020.
     Am J Gastroenterol. 2024;119:382-387.
     PubMed     Abstract available
     
     
     
147. JULIEN J, Ayer T, Tapper EB, Chhatwal J, et al
     The Rising Costs of Alcohol-Associated Liver Disease in the United States.
     Am J Gastroenterol. 2024;119:270-277.
     PubMed     Abstract available
     
     
     January 2024
148. GE J, Chen IY, Pletcher MJ, Lai JC, et al
     How I Approach It: Prompt Engineering for Generative Artificial Intelligence (GAI) in Gastroenterology and Hepatology.
     Am J Gastroenterol. 2024 Jan 31. doi: 10.14309/ajg.0000000000002689.
     PubMed    
     
     
     
149. CHARA BS, Hara KS, Penrice D, Schmidt KA, et al
     ARTIFICIAL INTELLIGENCE-ENABLED STOOL ANALYSIS FOR LACTULOSE TITRATION ASSISTANCE IN HEPATIC ENCEPHALOPATHY VIA A SMARTPHONE APPLICATION.
     Am J Gastroenterol. 2024 Jan 19. doi: 10.14309/ajg.0000000000002656.
     PubMed     Abstract available
     
     
     
150. BLOOM PP, Bajaj JS
     The Current and Future State of Microbiome Therapeutics in Liver Disease.
     Am J Gastroenterol. 2024;119.
     PubMed    
     
     
     
151. KARNA R
     Continuing Medical Education Questions: January 2024.
     Am J Gastroenterol. 2024;119:27.
     PubMed     Abstract available
     
     
     
152. NICOLETTI P, Dellinger A, Li YJ, Barnhart H, et al
     HLA-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans.
     Am J Gastroenterol. 2024;119:200-202.
     PubMed     Abstract available
     
     
     December 2023
153. FAGAN A, Gallagher ML, Mousel T, Davis BC, et al
     AI evaluation of Stool Quality Guides Management of Hepatic Encephalopathy using a Smartphone App.
     Am J Gastroenterol. 2023 Dec 28. doi: 10.14309/ajg.0000000000002646.
     PubMed     Abstract available
     
     
     
154. MUI BG, Grinspan LT, Crismale JF
     Variations in practice among cirrhotic patients with portal vein thrombosis and esophageal varices: a North American survey study.
     Am J Gastroenterol. 2023 Dec 26. doi: 10.14309/ajg.0000000000002640.
     PubMed     Abstract available
     
     
     
155. MULGAONKAR A, Huang DQ, Siddiqi H, Fowler K, et al
     Cost-Effectiveness Analysis of HCC Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis using US Visualization Score C-Triggered Abbreviated MRI.
     Am J Gastroenterol. 2023 Dec 26. doi: 10.14309/ajg.0000000000002636.
     PubMed     Abstract available
     
     
     
156. PRICE JC, Springer G, Seaberg EC, Budoff MJ, et al
     High incidence rate of CT-measured steatotic liver disease in men with and without HIV infection.
     Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002633.
     PubMed     Abstract available
     
     
     
157. LEE JD, Gounko D, Lee JA, Mukherjee T, et al
     Assisted Reproductive Technology Treatment Outcomes in Women With Liver Disease.
     Am J Gastroenterol. 2023;118:2184-2190.
     PubMed     Abstract available
     
     
     November 2023
158. DAHER D, El Dahan KS, Yekkaluri S, Gopal P, et al
     Proportion Time Covered by Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
     Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002596.
     PubMed     Abstract available
     
     
     
159. HASHMI I, Chadha N, McIntosh G, Sterling R, et al
     Quality Improvement for Health Care Providers in Gastroenterology and Hepatology.
     Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002609.
     PubMed    
     
     
     
160. KULKARNI AV, Avadhanam M, Karandikar P, Rakam K, et al
     Antibiotics with or without Rifaximin for acute hepatic Encephalopathy in critically ill patients with cirrhosis: A double-blind, randomized controlled (ARiE) trial.
     Am J Gastroenterol. 2023 Nov 9. doi: 10.14309/ajg.0000000000002575.
     PubMed     Abstract available
     
     
     
161. BAJAJ JS, Kamath PS, Reddy KR, Asrani SK, et al
     Predictors of Respiratory Failure Development in A Multi-Center Cohort of Inpatients with Cirrhosis.
     Am J Gastroenterol. 2023 Nov 8. doi: 10.14309/ajg.0000000000002574.
     PubMed     Abstract available
     
     
     
162. PATEL A, Bowman CA, Prause N, Kilaru SM, et al
     Outcomes of a Three-Year Quality Improvement Study to Improve Advance Care Planning in Patients with Decompensated Cirrhosis.
     Am J Gastroenterol. 2023 Nov 7. doi: 10.14309/ajg.0000000000002570.
     PubMed     Abstract available
     
     
     
163. WANG B, Zhou J, Wu X, Sun Y, et al
     Carvedilol plus NUCs for compensated HBV-cirrhosis patients under virological suppression: a randomised, open-label trial.
     Am J Gastroenterol. 2023 Nov 6. doi: 10.14309/ajg.0000000000002569.
     PubMed     Abstract available
     
     
     
164. YAGHOOBI M
     Continuing Medical Education Questions: November 2023.
     Am J Gastroenterol. 2023;118:1925.
     PubMed     Abstract available
     
     
     
165. KIM J, Zhang Y, Kim H, Zhang Y, et al
     A Comparative Study of Healthy Dietary Patterns for Incident and Fatal Digestive System Cancer.
     Am J Gastroenterol. 2023;118:2061-2070.
     PubMed     Abstract available
     
     
     
166. SQUIZZATO F, Abruzzino G, Piazza M
     Acute Liver Failure in a Patient With Previous Vascular Surgery for Bowel Ischemia.
     Am J Gastroenterol. 2023;118:1919.
     PubMed    
     
     
     
167. CHO Y, Chang Y, Ryu S, Kim C, et al
     History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study.
     Am J Gastroenterol. 2023;118:1980-1988.
     PubMed     Abstract available
     
     
     October 2023
168. LV XH, Lu Q, Deng K, Yang JL, et al
     Prevalence and characteristics of covert/minimal hepatic encephalopathy in patients with liver cirrhosis: A systematic review and meta-analysis.
     Am J Gastroenterol. 2023 Oct 19. doi: 10.14309/ajg.0000000000002563.
     PubMed     Abstract available
     
     
     
169. SILKE L, Donata G, Dominik G, Uli F, et al
     Endoscopic features of post-COVID-19 cholangiopathy and its management using ERCP.
     Am J Gastroenterol. 2023 Oct 16. doi: 10.14309/ajg.0000000000002562.
     PubMed     Abstract available
     
     
     
170. OZTURK NB, Jamil LH, Tapper EB
     Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients with Cirrhosis.
     Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002560.
     PubMed     Abstract available
     
     
     
171. PRASOPPOKAKORN T, Panarat P
     Disseminated Melioidosis infection involving hepatosplenomegaly and massive extramedullary hematopoiesis.
     Am J Gastroenterol. 2023 Oct 4. doi: 10.14309/ajg.0000000000002549.
     PubMed    
     
     
     
172. PULASKI M, Bittermann T, Taddei TH, Kaplan DE, et al
     The Association between Homelessness and Key Liver-Related Outcomes in Veterans with Cirrhosis.
     Am J Gastroenterol. 2023 Oct 2. doi: 10.14309/ajg.0000000000002535.
     PubMed     Abstract available
     
     
     
173. ONG J, Mandour MO, Allison M
     Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease.
     Am J Gastroenterol. 2023;118:1899.
     PubMed    
     
     
     September 2023
174. NACHEF C, Bousson V, Belmatoug N, Cohen-Solal M, et al
     Osteoporosis and fragility fractures in patients with cirrhosis evaluated for liver transplantation: Identification of high-risk patients based on computed tomography at evaluation.
     Am J Gastroenterol. 2023 Sep 20. doi: 10.14309/ajg.0000000000002507.
     PubMed     Abstract available
     
     
     
175. FENG X, Li H, Bajaj J, Moon AM, et al
     Endoscopic Ultrasound (EUS)-guided Sclerotherapy with Lauromacrogol: A Novel Therapy for A Giant Esophageal Hemangioma.
     Am J Gastroenterol. 2023 Sep 20. doi: 10.14309/ajg.0000000000002514.
     PubMed    
     
     
     July 2023
176. LARINO-NOIA J, Fernandez-Castroagudin J, de la Iglesia-Garcia D, Lazare H, et al
     Quality of Tissue Samples Obtained by Endoscopic Ultrasound-Guided Liver Biopsy: A Randomized, Controlled Clinical Trial.
     Am J Gastroenterol. 2023 Jul 14. doi: 10.14309/ajg.0000000000002375.
     PubMed     Abstract available
     
     
     March 2023
177. LIU Y, Guo G, Zheng L, Sun R, et al
     Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: A Randomized Clinical Trial.
     Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002238.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum